One explanation could be that the point of time at which RRBSO was performed was too late to attenuate breast cancer risk in this cohort, as the mean age of breast cancer onset is younger for BRCA1 than for BRCA2 pathogenic variant carriers. This evidence concerns the gene BRCA2 and breast cancer.